Acusphere Stock

Acusphere Equity Growth

The Year-over-Year Equity Growth of Acusphere (ACUS) as of Aug 5, 2026 is -97.88 %. In the previous year, Year-over-Year Equity Growth was -59.40 % — a change of 64.79% (lower).

Equity Growth

-97.88 %

YoY

64.79%

Last updated:

Year-over-Year Equity Growth of Acusphere is 2026 -97.88 % . Year-over-Year Equity Growth of Acusphere was 2025 -59.40 % . It decreases by 64.79% lower compared to the previous year.
Access this data via the Eulerpool API

Acusphere Stock analysis

What does Acusphere do? Acusphere Inc is a US-American company that was founded in 1993. It specializes in the development and marketing of advanced pharmaceuticals and therapeutic platforms in the fields of cardiology and pulmonology. The company is based in Lexington, Massachusetts and currently employs about 30 employees. The history of Acusphere goes back to the discovery of a new class of pharmaceutical agents, called microspheres. These spherical particles have a diameter of only a few micrometers and can have the ability to bind various therapeutic agents and release them in a targeted manner in the body. Acusphere has developed several innovative products and technologies based on these microspheres in recent years. One focus of the company is the development of therapies for patients with cardiovascular diseases such as heart failure or coronary artery disease. Another research area of ​​the company is the development of therapies for patients with lung diseases such as COPD or asthma. The business model of Acusphere is mainly based on the discovery and marketing of new drugs and therapies. In order to achieve these goals, the company works closely with leading scientific institutions and invests a significant portion of its budget in research and development. Acusphere is divided into several business areas, each of which includes different products and technologies. One of the most important business areas is the development of drugs for the treatment of cardiovascular diseases. An example of this is the drug EchoSphere, which was developed based on microspheres and is able to improve the oxygen supply to the heart muscle. Another important business area of ​​Acusphere is the development of products for the treatment of lung diseases such as COPD and asthma. For this purpose, the company has developed several new technologies that allow targeted delivery of medication to the lungs and its effects there. One of these technologies is the so-called Solutol technology, which allows medication to be concentrated in the alveoli of the lungs while avoiding unwanted side effects. In recent years, Acusphere has developed a number of innovative products and technologies that have great market potential due to their high efficacy and tolerability. The company is making every effort to bring these products to the market as quickly as possible and make a significant contribution to improving healthcare. Acusphere is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acusphere stock

Year-over-Year Equity Growth of Acusphere is -97.88 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Acusphere since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Acusphere historically and in real time.

Access this data via the Eulerpool API

Growth — Acusphere

All Key Metrics — Acusphere